HomeCompareTKBIF vs VICI

TKBIF vs VICI: Dividend Comparison 2026

TKBIF yields 1.58% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $966.8K in total portfolio value
10 years
TKBIF
TKBIF
● Live price
1.58%
Share price
$7.30
Annual div
$0.12
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$174.62
Full TKBIF calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — TKBIF vs VICI

📍 VICI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTKBIFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TKBIF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TKBIF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TKBIF
Annual income on $10K today (after 15% tax)
$134.02/yr
After 10yr DRIP, annual income (after tax)
$148.43/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $529,623.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TKBIF + VICI for your $10,000?

TKBIF: 50%VICI: 50%
100% VICI50/50100% TKBIF
Portfolio after 10yr
$505.4K
Annual income
$311,717.97/yr
Blended yield
61.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

TKBIF
No analyst data
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TKBIF buys
0
VICI buys
0
No recent congressional trades found for TKBIF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTKBIFVICI
Forward yield1.58%6.57%
Annual dividend / share$0.12$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$22.0K$988.8K
Annual income after 10y$174.62$623,261.32
Total dividends collected$1.7K$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TKBIF vs VICI ($10,000, DRIP)

YearTKBIF PortfolioTKBIF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$10,858$157.67$11,368$948.43$510.00VICI
2$11,778$159.99$13,339$1,493.16$1.6KVICI
3$12,764$162.20$16,326$2,426.21$3.6KVICI
4$13,822$164.29$21,123$4,112.15$7.3KVICI
5$14,956$166.26$29,379$7,368.23$14.4KVICI
6$16,171$168.13$44,804$14,191.64$28.6KVICI
7$17,473$169.90$76,658$29,972.12$59.2KVICI
8$18,868$171.57$150,894$71,015.81$132.0KVICI
9$20,361$173.14$350,814$193,582.47$330.5KVICI
10$21,961$174.62$988,809$623,261.32$966.8KVICI

TKBIF vs VICI: Complete Analysis 2026

TKBIFStock

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Full TKBIF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this TKBIF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TKBIF vs SCHDTKBIF vs JEPITKBIF vs OTKBIF vs KOTKBIF vs MAINTKBIF vs NNNTKBIF vs EPRTTKBIF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.